Methylphenidate is not clastogenic in cultured human lymphocytes and in the mouse bone-marrow micronucleus test

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 607, Issue 2, 2006, Pages 153-159

  Suter, Willi ^a   Martus, Hans Joerg ^a   Elhajouji, Azeddine ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chromosome aberrations; Clastogenicity; Cytogenetic effects; Methylphenidate; Micronucleus test; MPH; Ritalin

Indexed keywords

CLASTOGEN; METHYLPHENIDATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CHROMOSOME ABERRATION; CONTROLLED STUDY; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LYMPHOCYTE; LYMPHOCYTE CULTURE; MICRONUCLEUS TEST; MOUSE; MUTAGENICITY; NONHUMAN; NUMERICAL CHROMOSOME ABERRATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; STRUCTURAL CHROMOSOME ABERRATION; TOXICITY TESTING;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKOCYTES, MONONUCLEAR; METHYLPHENIDATE; MICE; MICE, INBRED STRAINS; MICRONUCLEUS TESTS; MODELS, CHEMICAL; MUTAGENS; TIME FACTORS;

EID: 33746275239     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2006.02.004     Document Type: Article

References (32)

1. Wilens T.E., and Biederman J. The stimulants. Psychiatry Clin. North. Am. 15 (1992) 191-222
2. Barkley R.A. A review of stimulant drug research with hyperactive children. J. Child Psychol. Psychiatry 18 (1977) 137-165
3. K. Kavale. The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis, J. Learn. Disabil. 15, 280-289.
4. Greenhill L.L. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr. Clin. North. Am. 15 (1992) 1-27
5. Teo S.K., San R.H., Wagner V.O., Gudi R., Stirling D.I., Thomas S.T., and Khetami V.D. d-Methylphenidate is non-genotoxic in in vitro and in vivo assays. Mutation Res. 537 (2003) 67-79
6. ICH Harmonised Tripartite Guideline (S2A), Guidance on specific aspects of regulatory genotoxicity tests (1995).
7. ICH Harmonised Tripartite Guideline (S2B), Genotoxicity: a standard battery for genotoxicity testing of pharmaceuticals (1997).
8. Mortelmans K., Haworth S., Lawlor T., Speck W., Tainer B., and Zeiger E. Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. Environ. Mol. Mutagenesis 8 Suppl. 7 (1986) 1-119
9. Rudd C.J., Mitchell A.D., and Spalding J. L5178Y mouse lymphoma mutagenesis assay of coded chemicals incorporating analyses of the colony size distribution. Environ. Mol. Mutagenesis 5 (1983) 419
10. Galloway S.M., Armstrong M.J., Reuben C., Colman S., Brown B., Cannon C., Bloom A.D., Nakamura F., Ahmed M., Duk S., Rimpo J., Margolin B.H., Resnick M.A., Anderson B., and Zeiger E. Chromosomal aberrations and sister chromatid exchanges in Chinese hamster ovary cells: evaluations of 108 chemicals. Environ. Mol. Mutagenesis 10 Suppl. 10 (1987) 1-175
11. Walker A.P., and Dumars K.P. Commonly used pediatric drugs, sister chromatid exchanges and the cell cycle. Am. J. Hum. Genet. 29 (1977) 110A
12. El-Zein R.A., Abdel-Rahman S., Hay M.J., Lopez M.S., Bondy M.L., Morris D.L., and Legator M.L. Cytogenetic effects in children treated with methylphenidate. Cancer Lett. 230 2 (2005) 284-291
13. OECD In vitro Mammalian Chromosome Aberration Test, OECD guidelines for the testing of chemicals 473, 21 July 1997.
14. Dean B.J., and Danford N. Assays for the detection of chemically-induced chromosome damage in cultured mammalian cells. In: Venitt S., and Parry J.M. (Eds). Mutagenicity Testing: A Practical Approach (1985), Oxford IRL Press 187-232
15. Savage J.R.K. Annotation: classification and relationships of induced chromosomal structural changes. J. Med. Genet. 13 (1976) 103-122
16. D. Scott, N.D. Danford, B.J. Dean, D. Kirkland, C.R. Richardson,, In vitro chromosome aberration assays, in: B.J., Dean (Ed.), Report of the Sub-Committee on Guidelines for Mutagenicity Testing, Swansea, United Kingdom Environmental Mutagen Society, 1983, pp. 41-64.
17. Mac Gregor J.T., Heddle J.A., Hite M., and Margolin B.H. Guidelines for the conduct of micronucleus assays in mammalian bone marrow erythrocytes. Mutation Res. 189 (1987) 103-112
18. OECD Mammalian Erythrocyte Micronucleus Test, OECD guidelines for the testing of chemicals 474, 21 July 1997.
19. Brusick D. Genotoxic effects in cultured mammalian cells produced by low pH treatment conditions and increased ion concentrations. Environ. Mol. Mutagen. 8 (1986) 879-886
20. Kirkland D. Chromosomal aberration tests in vitro: problems with protocol design and interpretation of results. Mutagenesis 7 (1992) 95-106
21. Kirkland D., Aardema M., Henderson L., and Mueller L. Evaluation of the ability of a battery of three in vitro genotoxicity test to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predicitivity. Mutation Res. 584 (2005) 1-256
22. National Toxicology Program, Technical Report Series. Toxicology and carcinogenesis studies of methylphenidate hydrochloride (CAS No. 298-59-9) in F344/N rats and B6C3F1 mice. No. 439 (1995) 1-294.
23. Redalieu E., Bartlett M.F., Waldes L.M., Darrow W.R., Egger H., and Wagner W.E. A study of methylphenidate in man with respect to its major metabolite. Drug Metabolism Disposition 10 (1982) 708-709
24. Markowitz J.K., Straughn A.B., Patrick K.S., DeVane C.L., Pestreich L., Lee J., Wang Y., and Muniz R. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin. Pharmacokinet. 42 (2003) 393-401
25. 14C studies in man and animals. J. Pharmacol. Exp. Ther. 191 (1974) 535-547
26. Srinivas N.R., Hubbard J.W., Korchinski E.D., and Midha K.K. Enantioselective pharmacokinetics of dl-threo methylphenidate in humans. Pharm. Res. 10 (1993) 14-21
27. Patrick K.S., Kilts C.D., and Breese G.R. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J. Med. Chem. 24 (1981) 1237-1240
28. Preston J.R., Kollins S.H., Swanson J.M., Greenhill L.L., Wigal T., Elliott G.R., and Vitiello B. Comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al. Cancer Lett. 230 2 (2005) 292-294
29. Kocisova J., Roessner P., Pinkova B., Bavorova H., and Sram R.J. Mutagenicity studies on paracetamol in human volunteers. I. Cytogenetic analysis of peripheral lymphocytes and lipid peroxidation in plasma. Mutation Res. 209 (1988) 161-165
30. Hongslo J.K., Brogger A., Bjorge C., and Holme J.A. Increased frequency of sister chromatid exchange and chromatid breaks in lymphocytes after treatment of human volunteers with therapeutic doses of paracetamol. Mutation Res. 261 (1991) 1-8
31. Kirkland D.J., Dresp J.H., Marshall R.R., Baumeister M., Gerloff C., and Gocke E. Normal chromosomal aberration frequencies in peripheral lymphocytes of healthy human volunteers exposed to a maximum daily dose of paracetamol in a double blind trial. Mutation Res. 279 (1992) 181-194
32. Hoffmann H., and Speit G. Assessment of DNA damage in peripheral blood of heavy smokers with the comet assay and the micronucleus test. Mutation Res. 581 (2005) 105-114